Apart from EGFR-targeting monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs) are in clinical use and approved for fist line therapy in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.